Shai Novik is the co-founder and Executive Chairman of the Board of Enlivex Therapeutics (Nasdaq: ENLV), a clinical stage immunotherapy company developing Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state as a potential novel therapy for life-threatening or debilitating diseases such as sepsis and osteoarthritis, which involve acute or chronic inflammation not resolvable by existing therapeutics. He previously founded (2005) and managed PROLOR Biotech, led its listing on the NYSE in 2010 and its sale in 2013, in a $590 million transaction. Mr. Novik executed a strategic partnership with Pfizer for PROLOR’s lead drug product, Ngenla®, a deal that included a $295 million upfront payment, an additional $275 million upon regulatory approval and profit sharing at revenue stage. Ngenla® recently obtained marketing approvals in 43 countries, including Australia, Canada, Japan, Europe & United States, positioning Pfizer as the leader in the $4 billion global market for growth hormone deficiencies. Mr. Novik is the co-founder and board member of Cortex Therapeutics, which is focused on developing and commercializing anti-aging therapeutics for the eyes and the brain. Previously, Mr. Novik served as Chief Operating Officer, Head of Strategic Planning and Head of Investment Committee of THCG, Inc., a NYC-based technology and life sciences venture capital firm. THCG was a portfolio company of Greenwich Street Partners, one of the largest U.S. private equity funds. Mr. Novik received his M.B.A, with distinction, from Cornell University.